Corporate | 27 July 2016 09:00
Carl Zeiss Meditec Recruits James V. Mazzo to Lead its Newly Consolidated Ophthalmology Organization
|
DGAP-News: Carl Zeiss Meditec AG / Key word(s): Change of Personnel
Jena, Germany, July 27
th
, 2016
James V. Mazzo will join Carl Zeiss Meditec as Global President of Ophthalmology with responsibility for the new Strategic Business Unit Ophthalmology as well as Carl Zeiss Meditec’s U.S. Sales and Service Center. Jim Mazzo is one of the industry’s best known and most respected business leaders with over 35 years of ophthalmic experience. He spent over 20 years leading Allergan’s North American and European eye care organizations. He led the public spin-off of AMO as Chairman/CEO, built that organization into a leading company in refractive, cataract and eye care products. In 2009 Abbott Labs purchased AMO and Mazzo was selected as EVP to lead Abbott’s global ophthalmology business. He left Abbott in 2013 to become executive chair and CEO of AcuFocus and Executive Chair of Neurotech. In a joint statement by Executive and Supervisory Board of Carl Zeiss Meditec AG, Dr. Ludwin Monz, President & CEO, and Dr. Michael Kaschke, Chairman of the Supervisory Board, comment: “We are excited to have Mr. Mazzo, one of the best experts in the ophthalmology industry join the ZEISS family. The re-organization and new leadership of the ophthalmology business will allow Carl Zeiss Meditec to extend the offering for ophthalmology and optometric customers globally. We see particular opportunities in extending the business in North America and parts of Asia.” “I am privileged and honored to be joining Carl Zeiss Meditec. The company has been an innovative leader in the industry for over 100 years. The broad line of technology and commitment to our industry is exciting. I look forward to continuing this excellence and building ZEISS into the premier ophthalmic franchise,” says James V. Mazzo. Carl Zeiss Meditec AG is listed on TecDAX of the German stock exchange and based in Jena, Germany. In fiscal year 2014/15 it achieved revenues of 1.04 bn EUR. The ZEISS Group owns 65% of the shares and the majority of Carl Zeiss Meditec AG. The ZEISS Group reached revenues of 4.5 bn EUR in the same fiscal year.
Contact for the press
Contact for investors
2016-07-27 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
|
| Language: | English | |
| Company: | Carl Zeiss Meditec AG | |
| Göschwitzer Str. 51-52 | ||
| 07745 Jena | ||
| Germany | ||
| Phone: | +49 (0)3641 220-0 | |
| Fax: | +49 (0)3641 220-112 | |
| E-mail: | investors.meditec@zeiss.com,info.meditec@zeiss.com | |
| Internet: | www.meditec.zeiss.de | |
| ISIN: | DE0005313704 | |
| WKN: | 531370 | |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Terminbörse EUREX | |
| End of News | DGAP News Service |